Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
Several peptides are studied for sleep — most notably DSIP (delta sleep-inducing peptide), the pineal peptide epitalon, and GH-axis peptides like CJC-1295/ipamorelin. Human evidence is small and preliminary, none is FDA-approved for sleep, and any use should be discussed with a healthcare provider.
Several peptides have been studied for their effects on sleep, most notably delta sleep-inducing peptide (DSIP), the pineal tetrapeptide epitalon, and growth-hormone-axis peptides. Early human and animal data are limited and mostly preliminary, and none are FDA-approved sleep drugs. This guide covers the mechanisms, evidence, safety, and 2026 regulatory status.
Peptides for sleep at a glance
- Most-studied for sleep: DSIP (delta sleep-inducing peptide) — a nonapeptide
- Other candidates: epitalon (melatonin/circadian rhythm), CJC-1295/ipamorelin (slow-wave sleep via the GH axis)
- Evidence level: small human trials and animal models; no large randomized controlled trials
- Commonly cited research framing: DSIP studied at ~25 nmol/kg by injection; epitalon in short multi-day courses
- FDA status (June 2026): none approved as sleep drugs; DSIP/Emideltide and epitalon removed from 503A Category 2 in April 2026 and scheduled for PCAC review on July 24, 2026
- Bottom line: promising mechanisms, thin clinical evidence — discuss with a healthcare provider
Which peptides are studied for sleep?
When people search for "peptides for sleep," they are usually referring to one of three groups, each with a different proposed mechanism:
- Delta sleep-inducing peptide (DSIP) — a naturally occurring nonapeptide (molecular weight ~849) first isolated from the cerebral venous blood of sleeping rabbits. It is the single most directly studied "sleep peptide" and is the subject of most of the older human data (Graf & Kastin, 1984, Neurosci Biobehav Rev).
- Epitalon (epithalon) — a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) proposed to support the pineal gland's own melatonin production and circadian rhythm rather than replacing melatonin from outside (Araj et al., 2025, Int J Mol Sci).
- Growth-hormone-axis peptides — including the GHRH analogue CJC-1295 and the growth hormone secretagogue ipamorelin. These are studied for body composition and recovery, and the sleep interest is indirect: growth hormone and deep sleep are biologically linked (Van Cauter et al., 2004, Growth Horm IGF Res).
It is important to be clear from the outset: the human evidence for all three is preliminary. The DSIP trials are decades old and small; epitalon's sleep data come largely from a single research group; and the GH-axis peptides have not been tested as sleep treatments in large trials.
How might DSIP affect sleep?
DSIP is a nonapeptide that, in animal models, has been observed to increase delta (slow-wave) sleep in rabbits, rats, and mice, while in cats the effect on REM sleep was more pronounced (Graf & Kastin, 1984, Neurosci Biobehav Rev). In cats, administration was associated with decreased sleep latency and an increase in deep slow-wave sleep specifically. The exact receptor or pathway DSIP acts through has never been fully resolved, and a 2006 review described it as a "still unresolved riddle" (Kovalzon & Strekalova, 2006, J Neurochem).
The most-cited human data come from two small studies. In six middle-aged chronic insomniacs, synthetic DSIP (25 nmol/kg) was associated with longer sleep duration and higher subjective sleep quality with fewer interruptions, slightly more REM sleep, and no reported daytime sedation (Schneider-Helmert & Schoenenberger, 1981, Experientia). In a separate open-label series, seven patients with severe insomnia received ten DSIP injections, and sleep reportedly normalized in six of seven, with follow-up of 3–7 months (Kaeser, 1984, Eur Neurol).
These are encouraging signals, but they are open-label, uncontrolled, and very small. Research in animal models suggests DSIP may support slow-wave sleep, but this has not been confirmed in modern randomized controlled trials. Consult your healthcare provider before starting any peptide protocol.
How might epitalon affect sleep?
Epitalon (epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, developed in Russia as a synthetic analogue of epithalamin, a natural pineal-gland extract (Araj et al., 2025, Int J Mol Sci). The proposed sleep mechanism is indirect: rather than acting as a sedative, epitalon is hypothesized to support the pineal gland's endogenous melatonin production and help restore a normal circadian melatonin rhythm.
The most-cited clinical work comes from the Khavinson/Korkushko group, which reported normalization of the circadian melatonin rhythm in older adults given short courses of the peptide. However, the 2025 International Journal of Molecular Sciences overview is candid about the limits: it notes that one study found a direct effect on melatonin synthesis in pinealocytes while another found no effect on pineal melatonin secretion, and that "information regarding critical issues about this peptide's safety is missing," recommending toxicity studies before it could be considered an approved active ingredient (Araj et al., 2025, Int J Mol Sci).
In short, epitalon's sleep rationale is plausible but the human evidence is thin and largely from a single group, with little independent replication. Consult your healthcare provider before starting any peptide protocol.
Do growth-hormone peptides like CJC-1295/ipamorelin improve deep sleep?
This is where mechanism and marketing often diverge. The biological link is real: growth hormone is preferentially secreted during deep, slow-wave sleep, and roughly the largest GH pulse of the day occurs shortly after sleep onset in association with the first slow-wave sleep period (Van Cauter et al., 2004, Growth Horm IGF Res). Critically, the relationship is reciprocal — GHRH itself increases both the duration and intensity of slow-wave sleep, while GHRH antagonists reduce both non-REM sleep and GH secretion (Van Cauter et al., 2004, Growth Horm IGF Res).
Because CJC-1295 is a GHRH analogue, it is reasonable to hypothesize that it could influence slow-wave sleep. But the direct evidence that CJC-1295 or ipamorelin improves sleep architecture in humans is largely absent — reports of "deeper sleep" are mostly anecdotal and uncontrolled. The published GH-and-sleep relationship establishes a plausible mechanism, not a proven sleep benefit for these specific peptides. We label this clearly as preclinical/mechanistic rather than clinically demonstrated. Consult your healthcare provider before starting any peptide protocol. For more on this pair, see our CJC-1295/ipamorelin guide.
What does the research actually support? (YMYL claim table)
| Claim | What the evidence actually shows | Source |
|---|---|---|
| "DSIP cures insomnia" | ❌ Never say this. Small open-label studies reported improved sleep duration/quality; no large RCTs | Schneider-Helmert & Schoenenberger, 1981; Kaeser, 1984 |
| DSIP and slow-wave sleep | Research in animal models suggests DSIP may increase slow-wave sleep; mechanism unresolved | Graf & Kastin, 1984; Kovalzon & Strekalova, 2006 |
| "Epitalon restores melatonin and fixes sleep" | Hypothesized to support circadian melatonin rhythm; evidence limited, conflicting, mostly single-group | Araj et al., 2025 |
| "GH peptides give you deep sleep" | GH and slow-wave sleep are linked, but no human trials show CJC-1295/ipamorelin improve sleep | Van Cauter et al., 2004 |
What are the safety considerations for sleep peptides?
The honest answer is that the long-term safety of these peptides is not well characterized, and that uncertainty is itself the most important safety point.
For DSIP, the small human studies reported no daytime sedation or notable side effects within their short windows (Schneider-Helmert & Schoenenberger, 1981, Experientia), but these trials involved only a handful of patients over weeks — not the months-to-years of data needed to establish a safety profile. For epitalon, the 2025 overview explicitly states that critical safety information is missing and calls for formal toxicity studies before it could be approved as an active ingredient (Araj et al., 2025, Int J Mol Sci).
Additional considerations apply broadly to research peptides:
- Source and purity risk: non-pharmacy "research-only" products are not manufactured to medical standards; contamination and mislabeling are documented concerns across the gray market.
- Drug interactions: any compound affecting sleep, melatonin, or the GH axis could interact with sedatives, hormones, or other medications.
- Vulnerable groups: none of these peptides has adequate safety data in pregnancy, breastfeeding, or people with cancer, endocrine, or psychiatric conditions.
Consult your healthcare provider before starting any peptide protocol, and bring a full list of your current medications and conditions. See our peptide safety guide for general sourcing and quality cautions.
Are sleep peptides legal? FDA status in 2026
No peptide is FDA-approved as a sleep medication, and Peptides.NYC does not sell peptides. The regulatory picture for several sleep-relevant peptides shifted meaningfully in 2026.
On April 15, 2026, the FDA announced it would remove 12 peptide bulk drug substances — including Emideltide/DSIP and epitalon — from Category 2 of its Section 503A bulk drug substances list (FDA, April 2026; Orrick analysis, 2026). Critically, removal from Category 2 is not approval and does not place a substance on the 503A Bulks List: these peptides remain ineligible for legal compounding until formally added to that list.
The next step is the Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, at which DSIP/Emideltide, epitalon, and semax are slated for review on July 24, alongside BPC-157, TB-500, KPV, and MOTs-C on July 23 (FDA; Orrick, 2026). A favorable vote could open a pathway to compounding through licensed 503A pharmacies as early as late 2026 or 2027 — but that outcome is not guaranteed. [VERIFY: exact post-PCAC timeline and any vote outcome, as the meeting falls after this article's publication date.]
Legal status varies by jurisdiction; consult a lawyer for binding advice. For the current landscape, see our 2026 peptide legal status tracker.
Frequently asked questions
Q: What is the best peptide for sleep? A: There is no clearly "best" peptide for sleep, because the human evidence is limited for all of them. DSIP (delta sleep-inducing peptide) is the most directly studied for sleep itself, with small older trials reporting improved sleep duration and quality. Epitalon is studied for circadian/melatonin support, and GH-axis peptides like CJC-1295/ipamorelin are linked to deep sleep only indirectly. None is FDA-approved as a sleep drug. Discuss any option with a healthcare provider.
Q: Does DSIP actually work for insomnia? A: In small, open-label human studies from the 1980s, DSIP was associated with longer, higher-quality sleep — in one series, sleep reportedly normalized in six of seven patients with severe insomnia (Kaeser, 1984). However, these studies were tiny and uncontrolled, and there are no modern large randomized trials. Research in animal models also suggests DSIP may increase slow-wave sleep. The signal is promising but not proven. Consult your healthcare provider.
Q: How is epitalon thought to help sleep? A: Epitalon is a pineal tetrapeptide (Ala-Glu-Asp-Gly) hypothesized to support the pineal gland's own melatonin production and help normalize the circadian rhythm, rather than acting as a direct sedative. Some research from a single Russian group reported melatonin-rhythm normalization in older adults, but a 2025 review noted conflicting findings and a lack of safety data (Araj et al., 2025). The sleep rationale is plausible but not well established.
Q: Do CJC-1295 and ipamorelin improve deep sleep? A: Growth hormone is naturally released during deep, slow-wave sleep, and GHRH increases slow-wave sleep, so there is a plausible mechanism (Van Cauter et al., 2004). However, there are no human trials showing that CJC-1295 or ipamorelin specifically improve sleep architecture. Reports of "deeper sleep" are anecdotal. They are studied mainly for body composition and recovery, not sleep. Consult your healthcare provider.
Q: Are sleep peptides FDA-approved? A: No. As of June 2026, no peptide is FDA-approved as a sleep or insomnia medication. In April 2026, the FDA removed DSIP/Emideltide and epitalon from 503A "Category 2," and they are scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026 — but removal from Category 2 is not approval, and these peptides are not yet eligible for legal compounding.
Q: What dose of DSIP is used in research? A: We do not provide dosing instructions. For context only, the most-cited human study used synthetic DSIP at about 25 nmol/kg by injection (Schneider-Helmert & Schoenenberger, 1981), and other reports describe short series of injections. These are research conditions, not a recommendation. Dosing should never be self-directed and must be personalized with a licensed healthcare provider.
Q: Are sleep peptides safe long-term? A: Long-term safety is largely unknown. Small DSIP studies reported no notable short-term side effects, but they covered only weeks in a few patients. A 2025 epitalon overview explicitly flagged missing safety data and called for toxicity studies (Araj et al., 2025). Gray-market sourcing adds purity and contamination risk. This uncertainty is the main reason to involve a healthcare provider before considering any peptide.
References
- Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981. PubMed PMID: 7028502
- Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984;23(5):386-388. PubMed PMID: 6391926
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. PubMed PMID: 6145137
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. PubMed PMID: 16539679
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. PMC11943447
- Van Cauter E, et al. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res. 2004;14 Suppl A:S10-17. PubMed PMID: 15135771
- U.S. Food & Drug Administration. Updates to the 503A bulk drug substances list; removal of 12 peptides from Category 2 and PCAC meeting schedule (July 23–24, 2026). April 15, 2026. Orrick analysis
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.